Comparison of chemiluminescence enzyme immunoassay (CLEIA) with ELISA for the determination of anti-cyclic citrullinated peptide antibodies

Ryo Tanaka, Masao Takemura, Masao Sato, Yasunori Yamada, Takahito Nakagawa, Takuro Horibe, Masato Hoshi, Hirofumi Otaki, Hiroyasu Ito, Mitsuru Seishima, Katsuji Shimizu

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Background: Autoantibodies against cyclic citrullinated peptide (anti-CCP) are sensitive and highly specific markers for rheumatoid arthritis (RA). We evaluated the analytical and diagnostic accuracy of chemiluminescence enzyme immunoassay (CLEIA) for anti-CCP antibodies, and compared it with that of ELISA. Methods: Ninety-nine RA patients who were diagnosed according to the American College of Rheumatology criteria, 16 patients with osteoarthritis, and 94 healthy subjects were included. Sera were used to assess the precision, functional sensitivity, and linearity of anti-CCP antibody determination by CLEIA and the correlation of anti-CCP antibody values between CLEIA and ELISA. Results: For anti-CCP antibodies by CLEIA, the total CV was 4.0 and 5.3% at 21.17 and 90 U/ml, respectively, and the lower limit of detection was 0.1 U/ml. The correlation of CLEIA (x) with ELISA (y) for anti-CCP was: y = 1.08x + 4.171, r = 0.9178 (p < 0.0001). No difference was observed in the sensitivity and specificity between CLEIA and ELISA. Conclusions: The automated CLEIA processing system for determining anti-CCP antibodies showed a good analytical performance, and suggested that the CLEIA system has a potential to provide clinically useful data within a short time.

Original languageEnglish
Pages (from-to)22-25
Number of pages4
JournalClinica Chimica Acta
Volume411
Issue number1-2
DOIs
Publication statusPublished - 04-01-2010

Fingerprint

Chemiluminescence
Luminescence
Immunoenzyme Techniques
Autoantibodies
Enzyme-Linked Immunosorbent Assay
Antibodies
Enzymes
Rheumatoid Arthritis
cyclic citrullinated peptide
Osteoarthritis
Limit of Detection
Healthy Volunteers
Sensitivity and Specificity
Processing
Serum

All Science Journal Classification (ASJC) codes

  • Biochemistry
  • Clinical Biochemistry
  • Biochemistry, medical

Cite this

Tanaka, Ryo ; Takemura, Masao ; Sato, Masao ; Yamada, Yasunori ; Nakagawa, Takahito ; Horibe, Takuro ; Hoshi, Masato ; Otaki, Hirofumi ; Ito, Hiroyasu ; Seishima, Mitsuru ; Shimizu, Katsuji. / Comparison of chemiluminescence enzyme immunoassay (CLEIA) with ELISA for the determination of anti-cyclic citrullinated peptide antibodies. In: Clinica Chimica Acta. 2010 ; Vol. 411, No. 1-2. pp. 22-25.
@article{b79111f1c5b7413bb52a64b3fb4bbba5,
title = "Comparison of chemiluminescence enzyme immunoassay (CLEIA) with ELISA for the determination of anti-cyclic citrullinated peptide antibodies",
abstract = "Background: Autoantibodies against cyclic citrullinated peptide (anti-CCP) are sensitive and highly specific markers for rheumatoid arthritis (RA). We evaluated the analytical and diagnostic accuracy of chemiluminescence enzyme immunoassay (CLEIA) for anti-CCP antibodies, and compared it with that of ELISA. Methods: Ninety-nine RA patients who were diagnosed according to the American College of Rheumatology criteria, 16 patients with osteoarthritis, and 94 healthy subjects were included. Sera were used to assess the precision, functional sensitivity, and linearity of anti-CCP antibody determination by CLEIA and the correlation of anti-CCP antibody values between CLEIA and ELISA. Results: For anti-CCP antibodies by CLEIA, the total CV was 4.0 and 5.3{\%} at 21.17 and 90 U/ml, respectively, and the lower limit of detection was 0.1 U/ml. The correlation of CLEIA (x) with ELISA (y) for anti-CCP was: y = 1.08x + 4.171, r = 0.9178 (p < 0.0001). No difference was observed in the sensitivity and specificity between CLEIA and ELISA. Conclusions: The automated CLEIA processing system for determining anti-CCP antibodies showed a good analytical performance, and suggested that the CLEIA system has a potential to provide clinically useful data within a short time.",
author = "Ryo Tanaka and Masao Takemura and Masao Sato and Yasunori Yamada and Takahito Nakagawa and Takuro Horibe and Masato Hoshi and Hirofumi Otaki and Hiroyasu Ito and Mitsuru Seishima and Katsuji Shimizu",
year = "2010",
month = "1",
day = "4",
doi = "10.1016/j.cca.2009.09.032",
language = "English",
volume = "411",
pages = "22--25",
journal = "Clinica Chimica Acta",
issn = "0009-8981",
publisher = "Elsevier",
number = "1-2",

}

Tanaka, R, Takemura, M, Sato, M, Yamada, Y, Nakagawa, T, Horibe, T, Hoshi, M, Otaki, H, Ito, H, Seishima, M & Shimizu, K 2010, 'Comparison of chemiluminescence enzyme immunoassay (CLEIA) with ELISA for the determination of anti-cyclic citrullinated peptide antibodies', Clinica Chimica Acta, vol. 411, no. 1-2, pp. 22-25. https://doi.org/10.1016/j.cca.2009.09.032

Comparison of chemiluminescence enzyme immunoassay (CLEIA) with ELISA for the determination of anti-cyclic citrullinated peptide antibodies. / Tanaka, Ryo; Takemura, Masao; Sato, Masao; Yamada, Yasunori; Nakagawa, Takahito; Horibe, Takuro; Hoshi, Masato; Otaki, Hirofumi; Ito, Hiroyasu; Seishima, Mitsuru; Shimizu, Katsuji.

In: Clinica Chimica Acta, Vol. 411, No. 1-2, 04.01.2010, p. 22-25.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Comparison of chemiluminescence enzyme immunoassay (CLEIA) with ELISA for the determination of anti-cyclic citrullinated peptide antibodies

AU - Tanaka, Ryo

AU - Takemura, Masao

AU - Sato, Masao

AU - Yamada, Yasunori

AU - Nakagawa, Takahito

AU - Horibe, Takuro

AU - Hoshi, Masato

AU - Otaki, Hirofumi

AU - Ito, Hiroyasu

AU - Seishima, Mitsuru

AU - Shimizu, Katsuji

PY - 2010/1/4

Y1 - 2010/1/4

N2 - Background: Autoantibodies against cyclic citrullinated peptide (anti-CCP) are sensitive and highly specific markers for rheumatoid arthritis (RA). We evaluated the analytical and diagnostic accuracy of chemiluminescence enzyme immunoassay (CLEIA) for anti-CCP antibodies, and compared it with that of ELISA. Methods: Ninety-nine RA patients who were diagnosed according to the American College of Rheumatology criteria, 16 patients with osteoarthritis, and 94 healthy subjects were included. Sera were used to assess the precision, functional sensitivity, and linearity of anti-CCP antibody determination by CLEIA and the correlation of anti-CCP antibody values between CLEIA and ELISA. Results: For anti-CCP antibodies by CLEIA, the total CV was 4.0 and 5.3% at 21.17 and 90 U/ml, respectively, and the lower limit of detection was 0.1 U/ml. The correlation of CLEIA (x) with ELISA (y) for anti-CCP was: y = 1.08x + 4.171, r = 0.9178 (p < 0.0001). No difference was observed in the sensitivity and specificity between CLEIA and ELISA. Conclusions: The automated CLEIA processing system for determining anti-CCP antibodies showed a good analytical performance, and suggested that the CLEIA system has a potential to provide clinically useful data within a short time.

AB - Background: Autoantibodies against cyclic citrullinated peptide (anti-CCP) are sensitive and highly specific markers for rheumatoid arthritis (RA). We evaluated the analytical and diagnostic accuracy of chemiluminescence enzyme immunoassay (CLEIA) for anti-CCP antibodies, and compared it with that of ELISA. Methods: Ninety-nine RA patients who were diagnosed according to the American College of Rheumatology criteria, 16 patients with osteoarthritis, and 94 healthy subjects were included. Sera were used to assess the precision, functional sensitivity, and linearity of anti-CCP antibody determination by CLEIA and the correlation of anti-CCP antibody values between CLEIA and ELISA. Results: For anti-CCP antibodies by CLEIA, the total CV was 4.0 and 5.3% at 21.17 and 90 U/ml, respectively, and the lower limit of detection was 0.1 U/ml. The correlation of CLEIA (x) with ELISA (y) for anti-CCP was: y = 1.08x + 4.171, r = 0.9178 (p < 0.0001). No difference was observed in the sensitivity and specificity between CLEIA and ELISA. Conclusions: The automated CLEIA processing system for determining anti-CCP antibodies showed a good analytical performance, and suggested that the CLEIA system has a potential to provide clinically useful data within a short time.

UR - http://www.scopus.com/inward/record.url?scp=70449536401&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=70449536401&partnerID=8YFLogxK

U2 - 10.1016/j.cca.2009.09.032

DO - 10.1016/j.cca.2009.09.032

M3 - Article

C2 - 19818336

AN - SCOPUS:70449536401

VL - 411

SP - 22

EP - 25

JO - Clinica Chimica Acta

JF - Clinica Chimica Acta

SN - 0009-8981

IS - 1-2

ER -